Piper Jaffray Has Increased Confidence in H&R Block (HRB) Post Investor Day ; PT Trimmed to $42

Pre-Open Stock Movers 12/08: (ONTX) (TXMD) (FCS) Higher; (RAS) (GEVO) (OUTR) Lower (more...)

Onconova Therapeutics, Inc. (NASDAQ: ONTX) 38.2% HIGHER; announced the presentation of data from an ongoing Phase 1/2 clinical trial of oral rigosertib and azacitidine in higher-risk myelodysplastic syndromes (HR-MDS) at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. --Combination Achieved 77% Overall Response Rate in all MDS Patients-- --Overall Response Rate of 84% in treatment-naïve MDS Patients-- --Response Rate of 64% in MDS Patients who had Previously Failed HMAs-- --Company to Provide Further Information on Next Steps for Combination Development Program at Investor Event in New York City on December... More

After-Hours Stock Movers 12/07: (TXMD) (ORIG) (CLLS) Higher; (OUTR) (UNFI) (CMG) Lower (more...)

TherapeuticsMD, Inc. (NYSE: TXMD) 35% HIGHER; announced positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free vaginal estradiol softgel, for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. VVA is a chronic condition affecting nearly half of postmenopausal women in the United States that can significantly impair their quality of life.

Outerwall... More

H&R Block (HRB) Misses Q2 EPS by 3c

H&R Block (NYSE: HRB) reported Q2 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $128 million versus the consensus estimate of $132.13 million.

"We are excited about the upcoming tax season, with a focus on executing... More